{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T22:18:39Z","timestamp":1794694719604,"version":"4.9.1"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T00:00:00Z","timestamp":1646870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T00:00:00Z","timestamp":1646870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1038\/s41584-022-00761-z","type":"journal-article","created":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T13:02:32Z","timestamp":1646917352000},"page":"205-216","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":156,"title":["Treatment of axial spondyloarthritis: an update"],"prefix":"10.1038","volume":"18","author":[{"given":"Abhijeet","family":"Danve","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2130-1246","authenticated-orcid":false,"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,10]]},"reference":[{"key":"761_CR1","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/ard.60.4.353","volume":"60","author":"A Boonen","year":"2001","unstructured":"Boonen, A. et al. Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann. Rheum. Dis. 60, 353\u2013358 (2001).","journal-title":"Ann. Rheum. Dis."},{"key":"761_CR2","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit, M. et al. The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann. Rheum. Dis. 68, 777\u2013783 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"761_CR3","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/art.41042","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward, M. M. et al. 2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 71, 1599\u20131613 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"761_CR4","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/art.39298","volume":"68","author":"MM Ward","year":"2016","unstructured":"Ward, M. M. et al. American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 68, 282\u2013298 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"761_CR5","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde, D. et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann. Rheum. Dis. 76, 978\u2013991 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"761_CR6","first-page":"CD002822","volume":"2008","author":"H Dagfinrud","year":"2008","unstructured":"Dagfinrud, H., Kvien, T. K. & Hagen, K. B. Physiotherapy interventions for ankylosing spondylitis. Cochrane Database Syst. Rev. 2008, CD002822 (2008).","journal-title":"Cochrane Database Syst. Rev."},{"key":"761_CR7","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00296-014-2965-7","volume":"34","author":"T O\u2019Dwyer","year":"2014","unstructured":"O\u2019Dwyer, T., O\u2019Shea, F. & Wilson, F. Exercise therapy for spondyloarthritis: a systematic review. Rheumatol. Int. 34, 887\u2013902 (2014).","journal-title":"Rheumatol. Int."},{"key":"761_CR8","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s13075-016-1180-1","volume":"18","author":"A Levitova","year":"2016","unstructured":"Levitova, A. et al. Clinical improvement and reduction in serum calprotectin levels after an intensive exercise programme for patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. Arthritis Res. Ther. 18, 275 (2016).","journal-title":"Arthritis Res. Ther."},{"key":"761_CR9","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3899\/jrheum.090655","volume":"37","author":"LA Passalent","year":"2010","unstructured":"Passalent, L. A., Soever, L. J., O\u2019Shea, F. D. & Inman, R. D. Exercise in ankylosing spondylitis: discrepancies between recommendations and reality. J. Rheumatol. 37, 835\u2013841 (2010).","journal-title":"J. Rheumatol."},{"key":"761_CR10","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1007\/s00296-016-3565-5","volume":"36","author":"S Fabre","year":"2016","unstructured":"Fabre, S. et al. Physical activity in patients with axial spondyloarthritis: a cross-sectional study of 203 patients. Rheumatol. Int. 36, 1711\u20131718 (2016).","journal-title":"Rheumatol. Int."},{"key":"761_CR11","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00296-019-04494-3","volume":"40","author":"EH Coulter","year":"2020","unstructured":"Coulter, E. H., McDonald, M. T., Cameron, S., Siebert, S. & Paul, L. Physical activity and sedentary behaviour and their associations with clinical measures in axial spondyloarthritis. Rheumatol. Int. 40, 375\u2013381 (2020).","journal-title":"Rheumatol. Int."},{"key":"761_CR12","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/RHU.0000000000000499","volume":"23","author":"M Kasapoglu Aksoy","year":"2017","unstructured":"Kasapoglu Aksoy, M., Birtane, M., Tas\u00b8tekin, N. & Ekuklu, G. The effectiveness of structured group education on ankylosing spondylitis patients. J. Clin. Rheumatol. 23, 138\u2013143 (2017).","journal-title":"J. Clin. Rheumatol."},{"key":"761_CR13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jbspin.2011.06.005","volume":"79","author":"A Sudre","year":"2012","unstructured":"Sudre, A., Figuereido, I. T., Lukas, C., Combe, B. & Morel, J. On the impact of a dedicated educational program for ankylosing spondylitis: effect on patient satisfaction, disease knowledge and spinal mobility, a pilot study. Jt. Bone Spine 79, 99\u2013100 (2012).","journal-title":"Jt. Bone Spine"},{"key":"761_CR14","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s00296-016-3549-5","volume":"36","author":"G Candelas","year":"2016","unstructured":"Candelas, G. et al. Benefit of health education by a training nurse in patients with axial and\/or peripheral psoriatic arthritis: a systematic literature review. Rheumatol. Int. 36, 1493\u20131506 (2016).","journal-title":"Rheumatol. Int."},{"key":"761_CR15","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.2147\/DDDT.S164562","volume":"12","author":"B Lisowska","year":"2018","unstructured":"Lisowska, B., Kosson, D. & Domaracka, K. Lights and shadows of NSAIDs in bone healing: the role of prostaglandins in bone metabolism. Drug. Des. Devel. Ther. 12, 1753\u20131758 (2018).","journal-title":"Drug. Des. Devel. Ther."},{"key":"761_CR16","first-page":"1805","volume":"33","author":"A Barkhuizen","year":"2006","unstructured":"Barkhuizen, A. et al. Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis. J. Rheumatol. 33, 1805\u20131812 (2006).","journal-title":"J. Rheumatol."},{"key":"761_CR17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3109\/09273941003768224","volume":"18","author":"RD Levinson","year":"2010","unstructured":"Levinson, R. D. & Rosenbaum, J. T. Nonsteroidal anti-inflammatory drugs for prophylaxis of acute anterior uveitis. Ocul. Immunol. Inflamm. 18, 69\u201371 (2010).","journal-title":"Ocul. Immunol. Inflamm."},{"key":"761_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010952.pub2","author":"FP Kroon","year":"2015","unstructured":"Kroon, F. P. et al. Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis). Cochrane Database Syst. Rev. https:\/\/doi.org\/10.1002\/14651858.CD010952.pub2 (2015).","journal-title":"Cochrane Database Syst. Rev."},{"key":"761_CR19","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1007\/s10067-005-0132-y","volume":"25","author":"J Zochling","year":"2006","unstructured":"Zochling, J., Bohl-B\u00fchler, M. H., Baraliakos, X., Feldtkeller, E. & Braun, J. Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis\u2013a population-based survey. Clin. Rheumatol. 25, 794\u2013800 (2006).","journal-title":"Clin. Rheumatol."},{"key":"761_CR20","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1002\/acr.24070","volume":"72","author":"JW Liew","year":"2020","unstructured":"Liew, J. W. et al. Nonsteroidal antiinflammatory drug use and association with incident hypertension in ankylosing spondylitis. Arthritis Care Res. 72, 1645\u20131652 (2020).","journal-title":"Arthritis Care Res."},{"key":"761_CR21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s40674-017-0061-3","volume":"3","author":"A Danve","year":"2017","unstructured":"Danve, A. & Raychaudhuri, S. P. Comorbidities in spondyloarthritis. Curr. Treat. Options Rheumatol. 3, 63\u201374 (2017).","journal-title":"Curr. Treat. Options Rheumatol."},{"key":"761_CR22","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","volume":"382","author":"N Bhala","year":"2013","unstructured":"Bhala, N. et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 382, 769\u2013779 (2013).","journal-title":"Lancet"},{"key":"761_CR23","doi-asserted-by":"crossref","first-page":"409","DOI":"10.7326\/M14-2470","volume":"163","author":"NN Haroon","year":"2015","unstructured":"Haroon, N. N., Paterson, J. M., Li, P., Inman, R. D. & Haroon, N. Patients with ankylosing spondylitis have increased cardiovascular and cerebrovascular mortality: a population-based study. Ann. Intern. Med. 163, 409\u2013416 (2015).","journal-title":"Ann. Intern. Med."},{"key":"761_CR24","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/art.21054","volume":"52","author":"A Wanders","year":"2005","unstructured":"Wanders, A. et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 52, 1756\u20131765 (2005).","journal-title":"Arthritis Rheum."},{"key":"761_CR25","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1136\/annrheumdis-2012-201370","volume":"71","author":"F Kroon","year":"2012","unstructured":"Kroon, F., Landew\u00e9, R., Dougados, M. & van der Heijde, D. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann. Rheum. Dis. 71, 1623\u20131629 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"761_CR26","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1136\/annrheumdis-2015-207897","volume":"75","author":"J Sieper","year":"2016","unstructured":"Sieper, J. et al. Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). Ann. Rheum. Dis. 75, 1438\u20131443 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"761_CR27","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/art.41206","volume":"72","author":"P Karmacharya","year":"2020","unstructured":"Karmacharya, P. et al. Effect of therapy on radiographic progression in axial spondyloarthritis: a systematic review and meta-analysis. Arthritis Rheumatol. 72, 733\u2013749 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"761_CR28","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/art.1780391209","volume":"39","author":"DO Clegg","year":"1996","unstructured":"Clegg, D. O. et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. 39, 2004\u20132012 (1996).","journal-title":"Arthritis Rheum."},{"key":"761_CR29","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1136\/ard.2006.054098","volume":"66","author":"H Haibel","year":"2007","unstructured":"Haibel, H. et al. No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Ann. Rheum. Dis. 66, 419\u2013421 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"761_CR30","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1002\/1529-0131(199911)42:11<2325::AID-ANR10>3.0.CO;2-C","volume":"42","author":"DO Clegg","year":"1999","unstructured":"Clegg, D. O., Reda, D. J. & Abdellatif, M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum. 42, 2325\u20132329 (1999).","journal-title":"Arthritis Rheum."},{"key":"761_CR31","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1002\/art.39772","volume":"68","author":"A Sepriano","year":"2016","unstructured":"Sepriano, A. et al. Effect of comedication with conventional synthetic disease-modifying antirheumatic drugs on retention of tumor necrosis factor inhibitors in patients with spondyloarthritis: a prospective cohort study. Arthritis Rheumatol. 68, 2671\u20132679 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"761_CR32","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1002\/art.39691","volume":"68","author":"MJ Nissen","year":"2016","unstructured":"Nissen, M. J. et al. The effect of comedication with a conventional synthetic disease-modifying antirheumatic drug on drug retention and clinical effectiveness of anti-tumor necrosis factor therapy in patients with axial spondyloarthritis. Arthritis Rheumatol. 68, 2141\u20132150 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"761_CR33","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1136\/annrheumdis-2014-206616","volume":"74","author":"E Lie","year":"2015","unstructured":"Lie, E. et al. The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study. Ann. Rheum. Dis. 74, 970\u2013978 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"761_CR34","first-page":"1613","volume":"79","author":"K Ben Abdelghani","year":"2020","unstructured":"Ben Abdelghani, K. et al. AB0637 efficacy of comedication of conventional synthetic DMARDs with TNF blockers in patients with axial spondyloarthritis. Ann. Rheum. Dis. 79, 1613\u20131614 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"761_CR35","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1146\/annurev.med.45.1.491","volume":"45","author":"KJ Tracey","year":"1994","unstructured":"Tracey, K. J. & Cerami, A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu. Rev. Med. 45, 491\u2013503 (1994).","journal-title":"Annu. Rev. Med."},{"key":"761_CR36","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/art.1780380407","volume":"38","author":"J Braun","year":"1995","unstructured":"Braun, J. et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum. 38, 499\u2013505 (1995).","journal-title":"Arthritis Rheum."},{"key":"761_CR37","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/art.11325","volume":"48","author":"JC Davis Jr.","year":"2003","unstructured":"Davis, J. C. Jr. et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 48, 3230\u20133236 (2003).","journal-title":"Arthritis Rheum."},{"key":"761_CR38","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","volume":"52","author":"D van der Heijde","year":"2005","unstructured":"van der Heijde, D. et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 52, 582\u2013591 (2005).","journal-title":"Arthritis Rheum."},{"key":"761_CR39","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","volume":"54","author":"D van der Heijde","year":"2006","unstructured":"van der Heijde, D. et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 54, 2136\u20132146 (2006).","journal-title":"Arthritis Rheum."},{"key":"761_CR40","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","volume":"58","author":"RD Inman","year":"2008","unstructured":"Inman, R. D. et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 58, 3402\u20133412 (2008).","journal-title":"Arthritis Rheum."},{"key":"761_CR41","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","volume":"73","author":"R Landew\u00e9","year":"2014","unstructured":"Landew\u00e9, R. et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann. Rheum. Dis. 73, 39\u201347 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"761_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005468.pub2","author":"LJ Maxwell","year":"2015","unstructured":"Maxwell, L. J. et al. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst. Rev. https:\/\/doi.org\/10.1002\/14651858.CD005468.pub2 (2015).","journal-title":"Cochrane Database Syst. Rev."},{"key":"761_CR43","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1093\/rheumatology\/keaa268","volume":"59","author":"AR Cruz-Machado","year":"2020","unstructured":"Cruz-Machado, A. R. et al. Effect of biologic disease-modifying anti-rheumatic drugs targeting remission in axial spondyloarthritis: systematic review and meta-analysis. Rheumatology 59, 3158\u20133171 (2020).","journal-title":"Rheumatology"},{"key":"761_CR44","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/art.40866","volume":"71","author":"A Deodhar","year":"2019","unstructured":"Deodhar, A. et al. A fifty-two-week, randomized, placebo-controlled trial of certolizumab pegol in nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 71, 1101\u20131111 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"761_CR45","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1136\/ard.2010.147744","volume":"70","author":"N Vastesaeger","year":"2011","unstructured":"Vastesaeger, N. et al. Predicting the outcome of ankylosing spondylitis therapy. Ann. Rheum. Dis. 70, 973\u2013981 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"761_CR46","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2014-000017","volume":"1","author":"JR Maneiro","year":"2015","unstructured":"Maneiro, J. R., Souto, A., Salgado, E., Mera, A. & Gomez-Reino, J. J. Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis. RMD Open 1, e000017 (2015).","journal-title":"RMD Open"},{"key":"761_CR47","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.3899\/jrheum.141278","volume":"42","author":"X Baraliakos","year":"2015","unstructured":"Baraliakos, X. et al. Predictors of clinical remission under anti-tumor necrosis factor treatment in patients with ankylosing spondylitis: pooled analysis from large randomized clinical trials. J. Rheumatol. 42, 1418\u20131426 (2015).","journal-title":"J. Rheumatol."},{"key":"761_CR48","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1093\/rheumatology\/kez657","volume":"59","author":"GJ Macfarlane","year":"2020","unstructured":"Macfarlane, G. J., Pathan, E., Jones, G. T. & Dean, L. E. Predicting response to anti-TNF\u03b1 therapy among patients with axial spondyloarthritis (axSpA): results from BSRBR-AS. Rheumatology 59, 2481\u20132490 (2020).","journal-title":"Rheumatology"},{"key":"761_CR49","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.semarthrit.2017.04.005","volume":"47","author":"A Deodhar","year":"2017","unstructured":"Deodhar, A. & Yu, D. Switching tumor necrosis factor inhibitors in the treatment of axial spondyloarthritis. Semin. Arthritis Rheum. 47, 343\u2013350 (2017).","journal-title":"Semin. Arthritis Rheum."},{"key":"761_CR50","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s41927-020-0118-z","volume":"4","author":"A Deodhar","year":"2020","unstructured":"Deodhar, A. et al. Unmet needs in ankylosing spondylitis patients receiving tumour necrosis factor inhibitor therapy; results from a large multinational real-world study. BMC Rheumatol. 4, 19 (2020).","journal-title":"BMC Rheumatol."},{"key":"761_CR51","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/art.23333","volume":"59","author":"MS Heiberg","year":"2008","unstructured":"Heiberg, M. S. et al. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum. 59, 234\u2013240 (2008).","journal-title":"Arthritis Rheum."},{"key":"761_CR52","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/jcph.1348","volume":"59","author":"J Wro\u0144ski","year":"2019","unstructured":"Wro\u0144ski, J. & Fiedor, P. The safety profile of tumor necrosis factor inhibitors in ankylosing spondylitis: are TNF inhibitors safer than we thought? J. Clin. Pharmacol. 59, 445\u2013462 (2019).","journal-title":"J. Clin. Pharmacol."},{"key":"761_CR53","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13075-020-02288-8","volume":"22","author":"SR Manica","year":"2020","unstructured":"Manica, S. R. et al. Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis: is the reason to switch relevant? Arthritis Res. Ther. 22, 195 (2020).","journal-title":"Arthritis Res. Ther."},{"key":"761_CR54","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/ng.2007.17","volume":"39","author":"PR Burton","year":"2007","unstructured":"Burton, P. R. et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat. Genet. 39, 1329\u20131337 (2007).","journal-title":"Nat. Genet."},{"key":"761_CR55","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jbspin.2006.11.005","volume":"74","author":"D Wendling","year":"2007","unstructured":"Wendling, D., Cedoz, J. P., Racadot, E. & Dumoulin, G. Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis. Jt. Bone Spine 74, 304\u2013305 (2007).","journal-title":"Jt. Bone Spine"},{"key":"761_CR56","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1186\/ar3370","volume":"13","author":"H Appel","year":"2011","unstructured":"Appel, H. et al. Analysis of IL-17+ cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res. Ther. 13, R95 (2011).","journal-title":"Arthritis Res. Ther."},{"key":"761_CR57","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten, D. et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N. Engl. J. Med. 373, 2534\u20132548 (2015).","journal-title":"N. Engl. J. Med."},{"key":"761_CR58","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40744-018-0123-5","volume":"5","author":"AJ Kivitz","year":"2018","unstructured":"Kivitz, A. J. et al. Efficacy and safety of secukinumab 150 mg with and without loading regimen in ankylosing spondylitis: 104-week results from MEASURE 4 Study. Rheumatol. Ther. 5, 447\u2013462 (2018).","journal-title":"Rheumatol. Ther."},{"key":"761_CR59","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s13075-017-1490-y","volume":"19","author":"K Pavelka","year":"2017","unstructured":"Pavelka, K. et al. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Res. Ther. 19, 285 (2017).","journal-title":"Arthritis Res. Ther."},{"key":"761_CR60","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","volume":"392","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde, D. et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet 392, 2441\u20132451 (2018).","journal-title":"Lancet"},{"key":"761_CR61","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/art.40753","volume":"71","author":"A Deodhar","year":"2019","unstructured":"Deodhar, A. et al. Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors. Arthritis Rheumatol. 71, 599\u2013611 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"761_CR62","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/art.41477","volume":"73","author":"A Deodhar","year":"2020","unstructured":"Deodhar, A. et al. Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: primary results of a randomized, placebo-controlled phase III study. Arthritis Rheumatol. 73, 110\u2013120 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"761_CR63","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(19)32971-X","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar, A. et al. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. Lancet 395, 53\u201364 (2020).","journal-title":"Lancet"},{"key":"761_CR64","first-page":"1014","volume":"80","author":"JC Wei","year":"2021","unstructured":"Wei, J. C. et al. Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial. Ann. Rheum. Dis. 80, 1014\u20131021 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"761_CR65","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/ni.1736","volume":"10","author":"W O\u2019Connor Jr.","year":"2009","unstructured":"O\u2019Connor, W. Jr. et al. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat. Immunol. 10, 603\u2013609 (2009).","journal-title":"Nat. Immunol."},{"key":"761_CR66","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13075-019-1882-2","volume":"21","author":"A Deodhar","year":"2019","unstructured":"Deodhar, A. et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res. Ther. 21, 111 (2019).","journal-title":"Arthritis Res. Ther."},{"key":"761_CR67","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","volume":"394","author":"D van der Heijde","year":"2019","unstructured":"van der Heijde, D. et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial. Lancet 394, 2108\u20132117 (2019).","journal-title":"Lancet"},{"key":"761_CR68","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","volume":"80","author":"A Deodhar","year":"2021","unstructured":"Deodhar, A. et al. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann. Rheum. Dis. 80, 1004\u20131013 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"761_CR69","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/art.41911","volume":"74","author":"A Deodhar","year":"2021","unstructured":"Deodhar, A. et al. Upadacitinib in active ankylosing spondylitis: 1-year results from the double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension. Arthritis Rheumatol. 74, 70\u201380 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"761_CR70","unstructured":"FDA. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions https:\/\/www.fda.gov\/drugs\/fda-drug-safety-podcasts\/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death (2022)."},{"key":"761_CR71","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.23471","volume":"58","author":"D van der Heijde","year":"2008","unstructured":"van der Heijde, D. et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum. 58, 1324\u20131331 (2008).","journal-title":"Arthritis Rheum."},{"key":"761_CR72","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1002\/art.23901","volume":"58","author":"D van der Heijde","year":"2008","unstructured":"van der Heijde, D. et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum. 58, 3063\u20133070 (2008).","journal-title":"Arthritis Rheum."},{"key":"761_CR73","doi-asserted-by":"crossref","first-page":"R127","DOI":"10.1186\/ar2794","volume":"11","author":"D van der Heijde","year":"2009","unstructured":"van der Heijde, D. et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res. Ther. 11, R127 (2009).","journal-title":"Arthritis Res. Ther."},{"key":"761_CR74","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/art.38070","volume":"65","author":"N Haroon","year":"2013","unstructured":"Haroon, N. et al. The impact of tumor necrosis factor \u03b1 inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum. 65, 2645\u20132654 (2013).","journal-title":"Arthritis Rheum."},{"key":"761_CR75","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/annrheumdis-2017-211544","volume":"77","author":"C Molnar","year":"2018","unstructured":"Molnar, C. et al. TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. Ann. Rheum. Dis. 77, 63\u201369 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"761_CR76","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/acr.23097","volume":"69","author":"F Maas","year":"2017","unstructured":"Maas, F. et al. Reduction in spinal radiographic progression in ankylosing spondylitis patients receiving prolonged treatment with tumor necrosis factor inhibitors. Arthritis Care Res. 69, 1011\u20131019 (2017).","journal-title":"Arthritis Care Res."},{"key":"761_CR77","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/annrheumdis-2017-212377","volume":"77","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde, D. et al. Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial. Ann. Rheum. Dis. 77, 699\u2013705 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"761_CR78","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/rheumatology\/key375","volume":"58","author":"J Braun","year":"2019","unstructured":"Braun, J. et al. Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study. Rheumatology 58, 859\u2013868 (2019).","journal-title":"Rheumatology"},{"key":"761_CR79","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13075-019-1911-1","volume":"21","author":"J Braun","year":"2019","unstructured":"Braun, J. et al. Spinal radiographic progression over 2 years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison. Arthritis Res. Ther. 21, 142 (2019).","journal-title":"Arthritis Res. Ther."},{"key":"761_CR80","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s40261-020-00886-7","volume":"40","author":"X Baraliakos","year":"2020","unstructured":"Baraliakos, X. et al. Comparison of the effects of secukinumab and adalimumab biosimilar on radiographic progression in patients with ankylosing spondylitis: design of a randomized, phase IIIb study (SURPASS). Clin. Drug Investig. 40, 269\u2013278 (2020).","journal-title":"Clin. Drug Investig."},{"key":"761_CR81","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40257-020-00578-0","volume":"22","author":"K Yang","year":"2021","unstructured":"Yang, K., Oak, A. S. W. & Elewski, B. E. Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review. Am. J. Clin. Dermatol. 22, 173\u2013192 (2021).","journal-title":"Am. J. Clin. Dermatol."},{"key":"761_CR82","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/art.40728","volume":"71","author":"A Deodhar","year":"2019","unstructured":"Deodhar, A. et al. Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheumatol. 71, 258\u2013270 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"761_CR83","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","volume":"77","author":"D Baeten","year":"2018","unstructured":"Baeten, D. et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann. Rheum. Dis. 77, 1295\u20131302 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"761_CR84","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/annrheumdis-2019-215356","volume":"78","author":"DG McGonagle","year":"2019","unstructured":"McGonagle, D. G., McInnes, I. B., Kirkham, B. W., Sherlock, J. & Moots, R. The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. Ann. Rheum. Dis. 78, 1167\u20131178 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"761_CR85","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1136\/annrheumdis-2018-213654","volume":"78","author":"S Siebert","year":"2019","unstructured":"Siebert, S., Millar, N. L. & McInnes, I. B. Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation? Ann. Rheum. Dis. 78, 1015\u20131018 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"761_CR86","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/art.38291","volume":"66","author":"JA Smith","year":"2014","unstructured":"Smith, J. A. & Colbert, R. A. Review: the interleukin-23\/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyond. Arthritis Rheumatol. 66, 231\u2013241 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"761_CR87","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0140-6736(18)31362-X","volume":"392","author":"R Landew\u00e9","year":"2018","unstructured":"Landew\u00e9, R. et al. Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study. Lancet 392, 134\u2013144 (2018).","journal-title":"Lancet"},{"key":"761_CR88","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/annrheumdis-2020-eular.1322","volume":"79","author":"F Van den Bosch","year":"2020","unstructured":"Van den Bosch, F. et al. OP0107 etanercept withdrawal and re-treatment in patients with inactive non-radiographic axial spondyloarthritis at 24 weeks: results of re-embark, an open-label, phase IV trial. Ann. Rheum. Dis. 79, 70\u201370 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"761_CR89","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1136\/annrheumdis-2019-216839","volume":"79","author":"RB Landew\u00e9","year":"2020","unstructured":"Landew\u00e9, R. B. et al. Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction. Ann. Rheum. Dis. 79, 920\u2013928 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"761_CR90","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1136\/annrheumdis-2020-219717","volume":"80","author":"RB Landew\u00e9","year":"2021","unstructured":"Landew\u00e9, R. B. et al. Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y). Ann. Rheum. Dis. 80, 1022\u20131030 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"761_CR91","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/acr.24184","volume":"73","author":"DO Lawson","year":"2021","unstructured":"Lawson, D. O. et al. Tumor necrosis factor inhibitor dose reduction for axial spondyloarthritis: a systematic review and meta-analysis of randomized controlled trials. Arthritis Care Res. 73, 861\u2013872 (2021).","journal-title":"Arthritis Care Res."},{"key":"761_CR92","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11926-017-0648-6","volume":"19","author":"A Danve","year":"2017","unstructured":"Danve, A. & Deodhar, A. Treat to target in axial spondyloarthritis: what are the issues? Curr. Rheumatol. Rep. 19, 22 (2017).","journal-title":"Curr. Rheumatol. Rep."},{"key":"761_CR93","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1136\/annrheumdis-2020-219585","volume":"80","author":"A Molto","year":"2021","unstructured":"Molto, A. et al. Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial. Ann. Rheum. Dis. 80, 1436\u20131444 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"761_CR94","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1136\/annrheumdis-2020-eular.1543","volume":"79","author":"A Molt\u00f3","year":"2020","unstructured":"Molt\u00f3, A. et al. THU0370 cluster-randomized pragmatic clinical trial evaluating the potential benefit of a tight-control and treat-to-target strategy in axial spondyloarthritis: the results of the TICOSPA trial. Ann. Rheum. Dis. 79, 417\u2013417 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"761_CR95","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/acr2.11174","volume":"2","author":"JW Liew","year":"2020","unstructured":"Liew, J. W. et al. Patient-reported disease activity in an axial spondyloarthritis cohort during the COVID-19 Pandemic. ACR Open Rheumatol. 2, 533\u2013539 (2020).","journal-title":"ACR Open Rheumatol."},{"key":"761_CR96","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.sleep.2012.03.002","volume":"13","author":"JH Kang","year":"2012","unstructured":"Kang, J. H. & Lin, H. C. Obstructive sleep apnea and the risk of autoimmune diseases: a longitudinal population-based study. Sleep. Med. 13, 583\u2013588 (2012).","journal-title":"Sleep. Med."},{"key":"761_CR97","doi-asserted-by":"crossref","first-page":"e222","DOI":"10.1097\/RHU.0000000000001612","volume":"28","author":"SM Son","year":"2020","unstructured":"Son, S. M., Kim, D. S. & Lee, J. S. Fibromyalgia in axial spondyloarthritis: a meta-analysis. J. Clin. Rheumatol. 28, e222\u2013e227 (2020).","journal-title":"J. Clin. Rheumatol."},{"key":"761_CR98","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/art.39666","volume":"68","author":"M Dougados","year":"2016","unstructured":"Dougados, M. et al. Rate and predisposing factors for sacroiliac joint radiographic progression after a two-year follow-up period in recent-onset spondyloarthritis. Arthritis Rheumatol. 68, 1904\u20131913 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"761_CR99","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1136\/annrheumdis-2020-216980","volume":"79","author":"D van der Heijde","year":"2020","unstructured":"van der Heijde, D. et al. Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study. Ann. Rheum. Dis. 79, 595\u2013604 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"761_CR100","unstructured":"Deodhar A. et al. Tofacitinib for the treatment of adult patients with ankylosing spondylitis: primary analysis of a phase 3, randomized, double-blind, placebo-controlled study [abstract]. Arthritis Rheumatol. https:\/\/acrabstracts.org\/abstract\/tofacitinib-for-the-treatment-of-adult-patients-with-ankylosing-spondylitis-primary-analysis-of-a-phase-3-randomized-double-blind-placebo-controlled-study\/ (2020)."},{"key":"761_CR101","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/S0140-6736(18)32463-2","volume":"392","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde, D. et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. Lancet 392, 2378\u20132387 (2018).","journal-title":"Lancet"},{"key":"761_CR102","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","volume":"72","author":"J Sieper","year":"2013","unstructured":"Sieper, J. et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann. Rheum. Dis. 72, 815\u2013822 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"761_CR103","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/art.38721","volume":"66","author":"M Dougados","year":"2014","unstructured":"Dougados, M. et al. Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 66, 2091\u20132102 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"761_CR104","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1002\/art.39257","volume":"67","author":"J Sieper","year":"2015","unstructured":"Sieper, J. et al. A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 67, 2702\u20132712 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"761_CR105","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1093\/rheumatology\/keg256","volume":"42","author":"H Haibel","year":"2003","unstructured":"Haibel, H. et al. Treatment of active ankylosing spondylitis with pamidronate. Rheumatology 42, 1018\u20131020 (2003).","journal-title":"Rheumatology"}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-022-00761-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-022-00761-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-022-00761-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T17:38:28Z","timestamp":1700329108000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-022-00761-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,10]]},"references-count":105,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["761"],"URL":"https:\/\/doi.org\/10.1038\/s41584-022-00761-z","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,10]]},"assertion":[{"value":"3 February 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A. Danve: research grants from Novartis, Lilly; advisory boards at Janssen, AbbVie and Amgen; member of the Spondyloarthritis Research and Treatment Network and the Assessment of Spondyloarthritis International Society. A. Deodhar: research grants from AbbVie, Celgene, Eli Lilly, Glaxo Smith Kline, Novartis, Pfizer and UCB; advisory boards and consulting at AbbVie, Amgen, Aurinia, Bristol Myers Squibb, Celgene, Eli Lilly, Glaxo Smith Kline, Janssen, MoonLake, Novartis, Pfizer and UCB; member of the Spondyloarthritis Research and Treatment Network, the Assessment of Spondyloarthritis International Society and the Scientific Advisory Board of Spondylitis Association of America.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}